Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Asahi Kasei Pharma.

    Client Virtual Booth

    ASAHI KASEI PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Asahi Kasei Pharma
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    Hibiya Mitsui Tower 1-1-2 Yurakucho, Chiyoda-ku
    Telephone
    Telephone
    +81-(0)3-6699-3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.asahikasei-pharma.co.jp/en/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basilea Announces CHF 5 Million Milestone Payment From Asahi Kasei Pharma For Antifungal Cresemba® (isavuconazole) in Japan

    Details:

    Under the terms of the initial agreement, Asahi Kasei Pharma received exclusive rights to develop and commercialize Basilea’s antifungal Cresemba (isavuconazole), an intravenous and oral azole antifungal, in Japan.


    Lead Product(s): Isavuconazonium Sulfate

    Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Basilea Pharmaceutica

    Deal Size: $72.3 million Upfront Cash: $7.5 million

    Deal Type: Licensing Agreement March 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan

    Details:

    Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.


    Lead Product(s): Apraglutide

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Peptide

    Recipient: VectivBio

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 13, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immu...

    Details:

    VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.


    Lead Product(s): VEL-101

    Therapeutic Area: Immunology Product Name: FR104

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Veloxis Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 18, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

    Details:

    The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-host disease in Japan.


    Lead Product(s): Apraglutide

    Therapeutic Area: Gastroenterology Product Name: FE203799

    Highest Development Status: Phase IIIProduct Type: Peptide

    Recipient: VectivBio

    Deal Size: $200.0 million Upfront Cash: $30.0 million

    Deal Type: Licensing Agreement March 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basilea’s Partner Asahi Kasei Pharma Filed New Drug Application For the Marketing Authorization of Isavuconazole in Japan

    Details:

    Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan.


    Lead Product(s): Isavuconazonium Sulfate

    Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Basilea Pharmaceutica

    Deal Size: $72.3 million Upfront Cash: $7.5 million

    Deal Type: Partnership September 30, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basilea’s Partner Asahi Kasei Pharma Prepares NDA Filing for the Marketing Authorization of Isavuconazole in Japan

    Details:

    The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses.


    Lead Product(s): Isavuconazonium Sulfate

    Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Basilea Pharmaceutica

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 26, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

    Details:

    Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.


    Lead Product(s): AK1780

    Therapeutic Area: Neurology Product Name: AK1780

    Highest Development Status: Phase IProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Eli Lilly

    Deal Size: $410.0 million Upfront Cash: $20.0 million

    Deal Type: Licensing Agreement January 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Basilea’s Partner Asahi Kasei Pharma Completes Patient Enrolment in Phase 3 Study with Antifungal Isavuconazole (Cresemba®) in Japan

    Details:

    The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.


    Lead Product(s): Isavuconazonium Sulfate

    Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Basilea Pharmaceutica

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 07, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search